Health & Fitness
Health and Fitness
Health and Fitness 
Tue, June 16, 2009
Mon, June 15, 2009
Vanguard Pharmaceutical Corp.: Vanguard Pharmaceutical Corporation Has Acquired a Natural Flu Remedy -- Swine Guard
SAN ANTONIO, TX--(Marketwire - June 15, 2009) - Vanguard Pharmaceutical Corporation (
-- Shikimic Acid a traditional Chinese medicine to treat influenza and colds by strengthening the immune system and by functioning as an anti- inflammatory. -- Echinacea Purpurea Extract stimulates the immune system, prevents upper respiratory tract infections, is a mild antibiotic that fights strep and staph infections, and produces interferon which increases antiviral activity by improving the migration of white blood cells to attack foreign microorganisms and toxins in the bloodstream. -- Microcrystalline Cellulose fortifies blood vessels, aids in the repair and maintenance of vital lungs, and improves the lymphatic system. -- Ascorbic Acid an antioxidant that enhances the immune system, helps regenerate wounds, protects against effects of stress, and helps prevent certain cancers. -- Goldenseal Root Extract enhances the immune function, relieves stress, is an energy boost and improves the libido. -- Burdock Root purifies the liver, neutralizes most poisons, and detoxifies the system. -- Licorice Root Extract treats sore throats and rejuvenates cells of the digestive system and liver. -- Shaitake Mushroom, Astragulus Root Extract, and Pau D'Arce Extract, all work to enhance the immune function.
Vanguard Pharmaceutical believes prevention is the key to fighting influenza. With the World Health Organization recently declaring a swine flu pandemic, it is our responsibility to prevent the spread by taking the necessary precautions.
About Vanguard Pharmaceutical
In an era of ageing populations, rising health care costs, and increasing cancer cases Vanguard's mission is to decrease health care expenditures by selling affordable oncology and generic drugs and by investing in research to find a noninvasive cure for cancer.
Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure. Vanguard is currently targeting Latin America for its oncology and generic pharmaceutical sales as it is believed to have a substantially unmet demand for advanced generics and entry into the market can be done with relative ease. Latin America is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009.
A noninvasive cure for cancer will revolutionize our health care system by highly reducing hospital stays as patients will not have to go through life threatening chemotherapy and radiation which could save health care systems billions of dollars. Vanguard's team is researching several new technologies such as telomerase inhibitor therapy, nanoparticle therapies, and low power radio frequency radiation. Vanguard plans to partner with established clinical centers and universities to further develop these technologies then license them out. It has also discussed performing trials in Latin American oncology centers.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.